Rolf Stahel joins Ergomed as Non-Executive Chairman

UK-based drug development services company Ergomed has announced the appointment of Rolf Stahel to its Board as Non-Executive Chairman.

Mr Stahel brings over 30 years’ experience in the global pharmaceutical industry. He led Shire Pharmaceuticals Group as Chief Executive Officer from March 1994 to 2003 and during his tenure implemented six mergers and acquisitions transforming the private $30 million company into a FTSE 100 company.

A Swiss national, Mr Stahel is a graduate in Business Studies (KSL, CH) and attended 97th AMP (Harvard). He worked for 27 years with Wellcome in Switzerland, Italy, Thailand, Singapore and the UK. As Regional Director, based in Singapore, Mr Stahel was responsible for 18 Pacific Rim countries. His last position with Wellcome was Director of Group Marketing, based in the UK covering Group Strategy, R&D portfolio evaluation, marketing of existing and new products and business development. In this position, he reported to the Chief Executive of Wellcome.